Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly

European Journal of Endocrinology

Volumn 139, Issue 4, 1998, Pages 387-394

  Plockinger U ^a,b   Perez Canto, A ^a   Emde, C ^a   Liehr, R M ^a   Hopfenmuller W ^a   Quabbe, H J ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GASTRITIS; HUMAN; MALE; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STOMACH MUCOSA; SUBCUTANEOUS DRUG ADMINISTRATION;

ACROMEGALY; ADULT; AGED; FEMALE; GASTRIC ACID; GASTRIC MUCOSA; GASTRINS; GASTROINTESTINAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PREOPERATIVE CARE;

EID: 0031786069     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1390387     Document Type: Article

References (42)

1. Quabbe H-J & Plöckinger U. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. Journal of Clinical Endocrinology and Metabolism 1989 68 873-881.
2. Melmed S, Ho K, Klibanski A, Reichlin S & Thorner M. Recent advances in pathogenesis, diagnosis, and management of acromegaly. Journal of Clinical Endocrinology and Metabolism 1995 80 3395-3402.
3. Plöckinger U, Reichel M, Fett U, Saeger W & Quabbe H-J. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. Journal of Clinical Endocrinology and Metabolism 1994 79 1416-1423.
4. Colao A, Ferone D, Cappabianca P, Del Basso De Caro ML, Marzullo P, Monticelli A et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 3308-3314.
5. Williams G, Fuessl H, Kraenzlin M & Bloom SR. Postprandial effects of SMS 201-995 on gut hormones and glucose tolerance. Scandinavian Journal of Gastroenterology 1986 21 (Suppl 119) 73-83.
6. Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C & Koop I. Effect of the somatostatin analogue Sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987 36 108-124.
7. Gyr KE & Meier R. Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. Metabolism 1992 41 (Suppl 2) 17-21.
8. Sachs G, Meyer-Rosberg K, Scott DR, Melchers K, Shin JM & Besancon M. Acid secretion and Helicobacter pylori. Digestion 1997 58 (Suppl 1) 8-13.
9. Kuipers EJ, Uyterlinde AM, Peña AS, Roosendaal R, Pals G, Nelis GF et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995 345 1525-1528.
10. Forman D, Webb P & Parsonnet J. Helicobacter pylori and gastric cancer. Lancet 1994 343 243-244.
11. International Agency For Research On Cancer. Schistosomes, liver flukes and H. pylori. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 1994 61 177-240.
12. Soybel DI & Modlin IM. Implications of sustained suppression of gastric acid secretion. American Journal of Surgery 1992 163 613-622.
13. Correa P. The gastric microenvironment determines Helicobacter pylori colonization. American Journal of Gastroenterology 1995 90 1379-1381.
14. Plöckinger U, Dienemann D & Ouabbe H-J. Gastrointestinal side-effects of octreotide during long term treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 1990 71 1658-1662.
15. Anderson JV, Catnach S, Lowe DG, Fairclough PD, Besser GM & Wass JAH. Prevalence of gastritis in patients with acromegaly: untreated and during treatment with octreotide. Clinical Endocrinology 1992 37 227-232.
16. Jones SL, Patchett S, Anderson JV, Farthing MJG, Besser GM & Wass JAH. Prevalence of Helicobacter pylori in acromegalic patients during treatment with octreotide. Clinical Endocrinology 1995 43 683-687.
17. Londong W, Angerer M, Kutz K, Landgraf R & Londong V. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration. Gastroenterology 1989 96 713-722.
18. Plöckinger U, Liehr R-M & Quabbe H-J. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-h intragastric pH values. Journal of Clinical Endocrinology and Metabolism 1993 77 157-162.
19. Ezzat S & Melmed S. Are patients with acromegaly at increased risk for neoplasia? Journal of Clinical Endocrinology and Metabolism 1991 72 245-249.
20. Ron E, Gridley G, Hrubec Z, Page W. Arora S & Fraumeni JF Jr. Acromegaly and gastrointestinal cancer. Cancer 1991 68 1673-1677.
21. Dixon MF, Genta RM, Yardley JH, Correa P, and the Participants in the International Workshop on the Histopathology of Gastritis, Houston 1994 Classification and grading of gastritis. The updated Sydney System. American Journal of Surgical Pathology 1996 20 1161-1181.
22. El-Zimaity HMT, Graham DY, Al-Assi MT, Malaty H, Karttunen TJ, Graham DP et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Human Pathology 1996 27 35-41.
23. Emde C, Garner A & Blum AL. Technical aspects of intraluminal pH-metry in man: current status and recommendations. Gut 1987 28 1177-1188.
24. Emde C. Graphical display and statistical evaluation of data gained by long-term ambulatory intragastric pH monitoring. Digestive Diseases 1990 8 (Suppl 1) 82-86.
25. Hunyady B, Juricskay I, Nagy L, Garamszegi M, Vincze A & Mozsik G. Statistical interpretation of the antisecretory effect of famotidine measured by intragastric pH-metry. European Journal of Clinical Pharmacology 1996 50 449-456.
26. Bordi C, Annibale B, Azzoni C, Marignani M, Ferraro G, Antonelli G et al. Endocrine cell growths in atrophic body gastritis. Critical evaluation of a histological classification. Journal of Pathology 1997 18 2339-346.
27. Lehy T, Dubrasquet M & Bonfils S. Effect of somatostatin on normal and gastric-stimulated cell proliferation in the gastric and intestinal mucosae of the rat. Digestion 1979 19 99-109.
28. Freston JW, Borch K, Brand SJ, Carlsson E, Creutzfeldt W, Håkanson R et al. Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. Digestive Diseases and Sciences 1995 40 (February 1995 Supplement) 50S-62S.
29. Sachs G & Prinz C. Gastric enterochromaffin-like cells and the regulation of acid secretion. News in Physiological Sciences 1996 11 57-62.
30. Fung LC & Greenberg GR. Characterization of somatostatin receptor subtypes mediating inhibition of nutrient-stimulated gastric acid and gastrin in dogs. Regulatory Peptides 1997 68 197-203.
31. Hollande F, Choquet A, Bali JP & Magous R. Short term inhibitory effect of somatostatin on gastric histamine synthesis. Endocrinology 1997 138 955-962.
32. Aurang K, Wang J & Lloyd KCK. Somatostatin inhibition of acid and histamine release by activation of somatostatin receptor subtype 2 receptors in rats. Journal of Pharmacology and Experimental Therapeutics 1997 281 245-252.
33. Larsson L-I, Goltermann N, Magistris L de, Rehfeld JF & Schwartz TW. Somatostatin cell processes as pathways for paracrine secretion. Science 1979 205 1393-1394.
34. Chew CS. Inhibitory action of somatostatin on isolated gastric glands and parietal cells. American Journal of Physiology 1983 245 G221-G229.
35. 2 receptor-mediated inhibition of parietal cell function in rat isolated gastric mucosa. British Journal of Pharmacology 1996 119 905-910.
36. Zaki M, Harrington L, McCuen R, Coy DH, Arimura A & Schubert ML. Somatostatin receptor subtype 2 mediates inhibition of gastrin and histamine secretion from human, dog, and rat antrum. Gastroenterology 1996 111 919-924.
37. Ferraro G, Annibale B, Marignani M, Azzoni C, D'Adda T, D'Ambra G et al. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. Journal of Clinical Endocrinology and Metabolism 1996 81 677-683.
38. Armstrong D & Blum AL. Circadian rhythms of gastric acidity in healthy man. Hepato-gastroenterology 1990 37 262-263.
39. Verdu EF, Fraser R, Murphy GM, Blum AL & Armstrong D. The origin of nocturnal intragastric pH rises in healthy subjects. Scandinavian Journal of Gast roenterology 1995 30 935-943.
40. Cilluffo T, Armstrong D, Castiglione F, Emde C, Galeazzi R, Gonvers J-J et al. Reproducibility of ambulatory gastric pH recordings in the corpus and antrum. Scandinavian Journal of Gastroenterology 1990 25 1076-1083.
41. 99mTc]EHIDA hepatobiliary scan. Digestive Diseases and Sciences 1994 39 284-288.
42. Modlin IM, Zhu Z, Tang LH, Kidd M, Lawton GP, Miu K et al. Evidence for a regulatory role for histamine in gastric enterochromaffin-like cell proliferation induced by hypergastrinemia. Digestion 1996 57 310-321.